This inventor holds 1 USPTO granted patent. Top assignee: Novartis Pharma Ag. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Attilio Bondanza: Innovator in Chimeric Antigen Receptor Technology
Introduction
Attilio Bondanza is a prominent inventor based in Basel, Italy. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptor (CAR) technology. His work has the potential to revolutionize cancer treatment and immunotherapy.
Latest Patents
Attilio Bondanza holds a patent for "Methods of Making Chimeric Antigen Receptor-Expressing Cells." This innovative approach enhances the ability of immune cells to target and destroy cancer cells, showcasing his commitment to advancing medical science. He has 1 patent to his name.
Career Highlights
Bondanza is currently employed at Novartis Pharma AG, a leading global healthcare company. His role at Novartis allows him to collaborate with some of the brightest minds in the industry, furthering his research and development efforts in CAR technology.
Collaborations
Throughout his career, Attilio has worked alongside notable colleagues, including Louise Mary Treanor and Michael R Greene. These collaborations have enriched his research and contributed to the advancement of innovative therapies.
Conclusion
Attilio Bondanza is a key figure in the field of biotechnology, with a focus on chimeric antigen receptor technology. His contributions are paving the way for new treatments in cancer therapy, and his work at Novartis Pharma AG continues to impact the medical community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile